Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1

Cancer Research

Volumn 70, Issue 3, 2010, Pages 948-956

  Lee, Yoon Jin ^a   Koch, Moritz ^a   Karl, Daniel ^a   Torres Collado, Antoni X ^b   Fernando, Namali T ^a   Rothrock, Courtney ^a   Kuruppu, Darshini ^a   Ryeom, Sandra ^c   Iruela Arispe, M Luisa ^b   Yoon, Sam S ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS1 PROTEIN; METALLOPROTEINASE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; THROMBOSPONDIN 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL LYSATE; COLON CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVATION; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN SECRETION;

ADAM PROTEINS; ANIMALS; BINDING SITES; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THROMBOSPONDIN 1; TRANSFECTION;

EID: 76249092135     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3094     Document Type: Article

References (29)

1. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009;29:789-91.
2. Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem Soc Trans 2003;31:20-4.
3. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65:3967-79.
4. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressordependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-8.
5. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004;36:1038-45.
6. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 2001;159:1949-56.
7. Gutierrez LS, Suckow M, Lawler J, Ploplis VA, Castellino FJ. Thrombospondin 1 - a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis 2003;24: 199-207.
8. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001;98:12485-90.
9. Hawighorst T, Oura H, Streit M, et al. Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 2002;21:7945-56.
10. Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-β-dependent and -independent mechanisms. Cancer Res 2001;61:7830-9.
11. Carlson CB, Lawler J, Mosher DF. Structures of thrombospondins. Cell Mol Life Sci 2008;65:672-86.
12. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
13. Lee NV, Sato M, Annis DS, et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J 2006;25: 5270-83.
14. Thai SN, Iruela-Arispe ML. Expression of ADAMTS1 during murine development. Mech Dev 2002;115:181-5.
15. UKCCCR guidelines for the use of cell lines in cancer research. Br J Cancer 2000;82:1495-509.
16. Fernando NT, Koch M, Rothrock C, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by upregulation of multiple proangiogenic factors. Clin Cancer Res 2008; 14:1529-39.
17. Lawler J, Sunday M, Thibert V, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998;101:982-92.
18. Silverstein RL, Febbraio M. CD36-TSP-HRGP interactions in the regulation of angiogenesis. Curr Pharm Des 2007;13:3559-67.
19. Ali NA, Gaughan AA, Orosz CG, et al. Latency associated peptide has in vitro and in vivo immune effects independent of TGF-β1. PLoS One 2008;3:e1914.
20. Shindo T, Kurihara H, Kuno K, et al. ADAMTS-1: a metalloproteinasedisintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest 2000;105:1345-52.
21. Libutti SA, Saltz LB, Tepper JE. Colon cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008, p. 1232-84.
22. Linehan WM, Rini BI, Yang JC. Cancer of the kidney. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008, p. 1331-57.
23. Slingluff CL, Flaherty K, Rosenberg SA, Reed PW. Cutaneous melanoma. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008, p. 1897-950.
24. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.
25. Rodriguez-Manzaneque JC, Westling J, Thai SN, et al. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun 2002; 293:501-8.
26. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;1765: 178-88.
27. Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci U S A 2003;100: 8621-3.
28. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138:707-17.
29. Iruela-Arispe ML. Regulation of thrombospondin1 by extracellular proteases. Curr Drug Targets 2008;9:863-8.